Research is a hotbed for business in Ann Arbor and NextGen Sciences is taking advantage of it. The drug research firm has been growing between 10 to 15 percent each year since its founding in 2001 and expects to create up to 15 jobs within the next year.
If the youth are the future then the future is now in Ann Arbor where one high school student won a $50,000 scholarship for conducting research for a vaccine.
Some businesses stay, some go over time. Rosebud Solutions not only came to Ann Arbor it plans to stay for a long time and add more jobs locally as it expands.
Third time is definitely the charm for Ann Arbor's NanoBio. The UofM spin-off recently received its third installment of venture capital ($10 million) and it hopes to create more research jobs in the near future.
Giving in the name of stem cells, research that is. That's what a pair of generous benefactors are doing at the University of Michigan to help provide more resources for stem cell research.
Rising health care costs top the list of employers' concerns from the private to the public sector, so it's logical that a company who can decrease health care costs would be growing. It's certainly the case for Ann Arbor's HealthMedia.
With a $200,000 loan from the state's Company Formation and Growth Fund in hand, Ann Arbor's Meditrina http://www.meditrina.com/Pharmaceuticals is poised to add four positions.
A drug some are calling the female Viagara is one step closer to market. Ophena, developed by Ann Arbor drug company QuatRX Pharmaceuticals Co., was designed to treat a post-menopausal condition that makes sexual activity difficult or painful. QuatRX recently reported good results from a late-stage study.
A tiny device developed by University of Michigan scientists has made the impossible possible - using the tiny nano-voltmeter, scientists have been able to measure the electric field inside a cell.
You may not know what a cytometer does, but here's what it means for one Michigan company: jobs, growth, expansion.
Our Partners
